No supplier or customer ties in STTK's filings yet. The map draws only what companies disclose to the SEC; ties named in other companies' filings join as the graph reads them.
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.
Nothing on the wire mentions STTK yet. Iris sweeps the public feeds every quarter hour; headlines land here the moment a sweep tags them.
How STTK has moved on past release days vs its typical ±4.9% day, and how often it closed up. Computed from daily closes — not a forecast.